We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Node Biopsy for Large Breast Tumors

By HospiMedica staff writers
Posted on 05 Sep 2005
A new study shows that even women with large breast tumors can benefit from a less-invasive biopsy method that avoids the pain and discomfort of full armpit node removal.

Lymphatic mapping and sentinel node biopsy, the standard of care for patients with small breast cancers, can now be used to determine how far a cancer has progressed into the lymph nodes in cases of large breast tumors. More...
This technique has not been used until now in women with large breast tumors because of lack of data proving its reliability. Researchers at the University of North Carolina at Chapel Hill School of Medicine (UNC, USA) have shown in a study of 21 patients that sentinel node biopsy, when performed before chemotherapy is given to shrink the tumor, is very reliable. The patients in the study had tumors large enough in relation to the size of the breast that the breast could not be preserved.

In sentinel node biopsy, a surgeon injects the area near the tumor with a blue dye, which follows the path that tumor cells most likely would take from the tumor to the lymph nodes. The surgeon removes only the nodes that initially absorb the dye. These are thought to be the "sentinel” nodes, the ones to which cancer cells are most likely to travel. If no cancer is found in the sentinel nodes, then no further nodes are removed.

"I think any woman diagnosed with breast cancer should ask her physician what role this technique might play in her overall treatment,” said lead author Dr. David W. Ollila, associate professor of surgery at UNC. The study's findings were reported in the September 2005 issue of the American Journal of Surgery.


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ureteral Dilatation Balloon
Dornier Equinox
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.